Conference Coverage

Paclitaxel Matches New Drugs as First-Line Breast Cancer Therapy


 

FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Dr. Rugo said she receives research funding from Abraxis BioScience, Bristol-Myers Squibb, and Roche/Genentech. Dr. Vogelzang said he is a consultant to Amgen, AVEO, Bayer, Celgene(U), Dendreon, Eisai, GE Healthcare, Genentech, GlaxoSmithKline, Johnson & Johnson, Keryx, Medscape, Novartis, Oncogenex, Pfizer, and Wilex; he receives honoraria from Amgen, Bayer, Clinical Care Options, Genentech, Imedex, Lilly, Lippincott, Williams, and Wilkins, Medscape, Novartis, Onyx, Pfizer, and Veridex; and he receives research funding from Algeta, Pfizer, Progenics, and Tokai Pharmaceuticals.

Pages

Recommended Reading

Urologists Back PSA Screening; Rail Against USPSTF's Position
MDedge Internal Medicine
Vismodegib Proves Promising for Operable BCCs
MDedge Internal Medicine
Intermittent Hormone Therapy Shortens Prostate Cancer Survival
MDedge Internal Medicine
T-DM1 Tops Capecitabine-Lapatinib in Advanced HER2-Positive Breast Cancer
MDedge Internal Medicine
Bevacizumab Beyond Progression Extends Survival in Metastatic CRC
MDedge Internal Medicine
Laparoscopy Tops Open Resection for Most Gastric Tumors
MDedge Internal Medicine
FDA: Drug Shortages Decline but Persist
MDedge Internal Medicine
Screening Colonoscopy Can Benefit Selected Elderly People
MDedge Internal Medicine
Hodgkin's Survivors Face High Breast Cancer Risk
MDedge Internal Medicine
Stanford Experience Shows Long Metastatic BCC Survival
MDedge Internal Medicine